Orforglipron: Research Profile, Dosages & Supplier Prices

GLP-1 agonist (small molecule) · Powder (oral small molecule) · Also known as: LY3502970, oral GLP-1 agonist

Orforglipron is a glp-1 agonist (small molecule) compound with a molecular weight of 882.9 g/mol and a research half-life of ~25-68 hours. Orforglipron is an oral, non-peptide small-molecule agonist of the GLP-1 receptor developed by Eli Lilly - a fundamentally different approach from injectable peptide agonists like semaglutide. Because it is not a peptide, it survives digestion, needs no food/water restrictions, and is far cheaper to manufacture at scale.

Research Use Only (RUO). Not for human or veterinary use. Not medical advice.

Sequence	Non-peptide small molecule (oral GLP-1R agonist)
Formula	C48H48F2N10O6
Mol. weight	882.9 g/mol
Half-life	~25-68 hours
Forms sold	Powder (oral small molecule)

What is Orforglipron?

Phase 2 and 3 trials have shown weight loss and glycemic effects approaching injectable GLP-1 agonists, positioning it as one of the most watched metabolic compounds in development. In research it is used to study biased GLP-1R signaling (it engages G-protein pathways with limited beta-arrestin recruitment) and as the reference oral GLP-1 agent. It appears in research catalogs alongside peptides because it targets the same receptor and research questions.

Mechanism of Action (Research Context)

Partial/biased agonist at the GLP-1 receptor binding a non-peptide allosteric site: activates Gs/cAMP signaling with minimal beta-arrestin recruitment and receptor internalization, sustaining signaling. Fully oral bioavailability unlike peptide GLP-1 agonists.

Research Areas

Oral GLP-1R agonismBiased GPCR signalingObesity and type 2 diabetes researchBeta-arrestin vs G-protein pathway studies

Orforglipron Dosages in Research

Research reference: 3-45 mg oral (trial doses)

Phase 2/3 trials used once-daily oral dosing up to 45 mg. No food restrictions required. Research-context only.

Dosage information is a summary of published laboratory research and is provided for informational purposes only. These compounds are not for human use.

Storage & Handling

Powder: room temperature desiccated or 2-8C. Stable small molecule - far less fragile than peptide GLP-1 agonists.

Orforglipron Supplier Price Comparison

No tracked suppliers stock Orforglipron yet — inventory syncs run continuously. Check our supplier reviews.

Orforglipron FAQ

No - it is a small molecule that activates the GLP-1 receptor through an allosteric site. Its oral bioavailability comes precisely from not being a peptide.

Oral semaglutide (Rybelsus) is a peptide requiring strict fasting administration and has low bioavailability; orforglipron is a true small molecule with no food restrictions and simpler manufacturing.

98%+ HPLC purity and mass spec identity at 882.9 Da. As a high-value small molecule, identity confirmation protects against substitution with cheaper GLP-1 research chemicals.

Age & Use Verification